[go: up one dir, main page]

SG10201808935WA - Targeted modification of rat genome - Google Patents

Targeted modification of rat genome

Info

Publication number
SG10201808935WA
SG10201808935WA SG10201808935WA SG10201808935WA SG10201808935WA SG 10201808935W A SG10201808935W A SG 10201808935WA SG 10201808935W A SG10201808935W A SG 10201808935WA SG 10201808935W A SG10201808935W A SG 10201808935WA SG 10201808935W A SG10201808935W A SG 10201808935WA
Authority
SG
Singapore
Prior art keywords
rat
locus
compositions
methods
germline
Prior art date
Application number
SG10201808935WA
Inventor
Jeffrey D Lee
Alexander Mujica
Wojtek Auerbach
Ka-Man Venus Lai
David M Valenzuela
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201808935WA publication Critical patent/SG10201808935WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

TARGETED MODIFICATION OF RAT GENOME Compositions and methods are provided for modifying a rat genomic locus of interest using a 5 large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat 10 ApoE locus, the rat Rag2 locus, the rat Ragl locus and/or the rat Rag2/Ragl locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline. [Figure 2] 15
SG10201808935WA 2013-04-16 2014-04-16 Targeted modification of rat genome SG10201808935WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812319P 2013-04-16 2013-04-16
US201361914768P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
SG10201808935WA true SG10201808935WA (en) 2018-11-29

Family

ID=51687240

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808935WA SG10201808935WA (en) 2013-04-16 2014-04-16 Targeted modification of rat genome
SG11201508028QA SG11201508028QA (en) 2013-04-16 2014-04-16 Targeted modification of rat genome

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201508028QA SG11201508028QA (en) 2013-04-16 2014-04-16 Targeted modification of rat genome

Country Status (25)

Country Link
US (5) US20140310828A1 (en)
EP (2) EP3456831B1 (en)
JP (1) JP6411463B2 (en)
KR (2) KR20200136508A (en)
CN (2) CN105308184B (en)
AU (2) AU2014253942B9 (en)
BR (1) BR112015026197B1 (en)
CA (1) CA2908697C (en)
CY (2) CY1120845T1 (en)
DK (2) DK2986729T3 (en)
ES (2) ES2699578T3 (en)
HR (2) HRP20181648T1 (en)
HU (2) HUE056903T2 (en)
IL (2) IL241856B (en)
LT (2) LT3456831T (en)
MX (1) MX369747B (en)
MY (1) MY177850A (en)
PL (2) PL3456831T3 (en)
PT (2) PT3456831T (en)
RS (2) RS62263B1 (en)
RU (1) RU2676708C2 (en)
SG (2) SG10201808935WA (en)
SI (2) SI3456831T1 (en)
SM (2) SMT202100516T1 (en)
WO (1) WO2014172489A2 (en)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2612903C2 (en) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Mouse producing binding proteins containing vl-domains
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP2847335B1 (en) * 2012-04-25 2018-06-27 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
LT2800811T (en) 2012-05-25 2017-09-11 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2900992C (en) 2013-02-20 2023-02-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
PL3456831T3 (en) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9663782B2 (en) * 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
DK3178928T3 (en) 2013-08-07 2020-08-24 Regeneron Pharma Pint-knockout mice with a premature, age-associated phenotype
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150079680A1 (en) * 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
SMT201800653T1 (en) * 2013-12-11 2019-01-11 Regeneron Pharma Methods and compositions for the targeted modification of a genome
MX388127B (en) 2013-12-11 2025-03-19 Regeneron Pharma METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME.
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
KR102276752B1 (en) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
US20150266976A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
SG11201609154TA (en) 2014-05-30 2016-12-29 Regeneron Pharma Humanized dipeptidyl peptidase iv (dpp4) animals
WO2015188109A1 (en) 2014-06-06 2015-12-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
EP3919621A1 (en) 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
US9902971B2 (en) 2014-06-26 2018-02-27 Regeneron Pharmaceuticals, Inc. Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3561052A1 (en) 2014-10-15 2019-10-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
EP3521437B1 (en) * 2014-11-21 2025-01-15 Regeneron Pharmaceuticals, Inc. Methods for targeted genetic modification using paired guide rnas
AU2015355546B2 (en) 2014-12-03 2021-10-14 Agilent Technologies, Inc. Guide RNA with chemical modifications
SI3808775T1 (en) * 2014-12-09 2024-08-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
MX388784B (en) * 2014-12-19 2025-03-20 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.
WO2016114972A1 (en) 2015-01-12 2016-07-21 The Regents Of The University Of California Heterodimeric cas9 and methods of use thereof
WO2016123243A1 (en) 2015-01-28 2016-08-04 The Regents Of The University Of California Methods and compositions for labeling a single-stranded target nucleic acid
US9944912B2 (en) 2015-03-03 2018-04-17 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2016149398A1 (en) 2015-03-16 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
KR102377189B1 (en) 2015-05-29 2022-03-22 리제너론 파마슈티칼스 인코포레이티드 Non-human animals having a disruption in a c9orf72 locus
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2996888A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
CA2995248A1 (en) 2015-09-02 2017-03-09 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
CN105177110A (en) * 2015-09-11 2015-12-23 中国科学院微生物研究所 Detection method of nucleic acid
CA3000816A1 (en) 2015-09-11 2017-03-16 The General Hospital Corporation Full interrogation of nuclease dsbs and sequencing (find-seq)
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
CA3000762A1 (en) 2015-09-30 2017-04-06 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
ES2872799T3 (en) 2015-11-20 2021-11-02 Regeneron Pharma Non-human animals that have a humanized lymphocyte activation gene 3
US20190249172A1 (en) 2016-02-18 2019-08-15 The Regents Of The University Of California Methods and compositions for gene editing in stem cells
EP3422845B1 (en) 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
CN109414414A (en) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 Method and composition for treating obesity and/or diabetes and for identifying candidate therapeutic agent
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US20210010022A1 (en) * 2016-05-27 2021-01-14 Cambridge Enterprise Limited Novel nucleic acid construct
HRP20250471T1 (en) 2016-06-03 2025-06-06 Regeneron Pharmaceuticals, Inc. RODENTS EXPRESSING EXOGENEOUS TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10221395B2 (en) * 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
KR20190041476A (en) 2016-07-29 2019-04-22 리제너론 파마슈티칼스 인코포레이티드 A mouse containing a mutation inducing the expression of C-truncated fibrilin-1
JP7231935B2 (en) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Adenosine nucleobase editors and their uses
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN107815465B (en) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
WO2018041119A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
WO2018064600A1 (en) * 2016-09-30 2018-04-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
EP3523426A4 (en) 2016-09-30 2020-01-22 The Regents of The University of California NOVEL RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE
US10669539B2 (en) 2016-10-06 2020-06-02 Pioneer Biolabs, Llc Methods and compositions for generating CRISPR guide RNA libraries
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018112278A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
JP7203427B2 (en) * 2017-02-14 2023-01-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Method for manipulating human induced pluripotent stem cells to generate liver tissue
EP3585158B1 (en) 2017-02-27 2023-07-05 Regeneron Pharmaceuticals, Inc. Rodent models of retinoschisis
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CN108467873B (en) * 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 Preparation method and application of CD132 gene-deleted immunodeficiency animal model
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
CN106987604B (en) * 2017-03-29 2021-05-28 北京希诺谷生物科技有限公司 Method for preparing atherosclerosis disease model dog
WO2018193457A1 (en) 2017-04-20 2018-10-25 Ramot At Tel-Aviv University Ltd. Recombination activating gene (rag) induced v(d)j gene targeting
BR112019021719A2 (en) 2017-04-21 2020-06-16 The General Hospital Corporation CPF1 VARIANT (CAS12A) WITH CHANGED PAM SPECIFICITY
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11326157B2 (en) 2017-05-25 2022-05-10 The General Hospital Corporation Base editors with improved precision and specificity
WO2018228534A1 (en) * 2017-06-16 2018-12-20 中国科学院上海生命科学研究院 Method for preparing immunodeficient rats and application thereof
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
KR102712142B1 (en) 2017-07-31 2024-10-07 리제너론 파마슈티칼스 인코포레이티드 Cas-transgenic mouse embryonic stem cells and mice and uses thereof
JP2020533957A (en) 2017-07-31 2020-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． CRISPR Reporter Non-Human Animals and Their Use
US11286468B2 (en) 2017-08-23 2022-03-29 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111315889A (en) * 2017-09-08 2020-06-19 生命技术公司 Methods and compositions for enhancing homologous recombination
BR112020006428A2 (en) * 2017-09-28 2020-09-24 Toolgen Incorporated artificial genome manipulation for regulation of gene expression
US11572574B2 (en) 2017-09-28 2023-02-07 Toolgen Incorporated Artificial genome manipulation for gene expression regulation
CN111386039B (en) 2017-09-29 2023-02-28 瑞泽恩制药公司 Genetically modified rodent genomes
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
IL311170A (en) * 2017-09-29 2024-04-01 Intellia Therapeutics Inc Compositions and methods for editing TTR genes and treating ATTR type amyloidosis
US11725228B2 (en) 2017-10-11 2023-08-15 The General Hospital Corporation Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
AU2018352592B2 (en) 2017-10-16 2025-03-27 Beam Therapeutics, Inc. Uses of adenosine base editors
CN116064611A (en) 2017-11-30 2023-05-05 瑞泽恩制药公司 Non-human animals comprising a humanized TRKB locus
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CN116349651A (en) 2018-03-19 2023-06-30 瑞泽恩制药公司 Transcriptional modulation in animals using the CRISPR/Cas system
KR20200135397A (en) 2018-03-24 2020-12-02 리제너론 파마슈티칼스 인코포레이티드 Genetically modified non-human animals for producing therapeutic antibodies against peptide-MHC complexes, methods of making the same
KR20210004994A (en) 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 Humanized rodents to test therapeutic agents
CN118325840A (en) 2018-03-27 2024-07-12 宾夕法尼亚大学董事会 Modified immune cells with enhanced functions and screening methods thereof
EP3781585A4 (en) 2018-04-17 2022-01-26 The General Hospital Corporation SENSITIVE IN VITRO TESTS FOR SUBSTRATE PREFERENCES AND SITE FOR NUCLEIC ACID BINDERS, MODIFIERS AND CLEAVAGE AGENTS
CN108624622A (en) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 A kind of genetically engineered cell strain that can secrete mouse interleukin -6 based on CRISPR-Cas9 systems structure
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
CN109868285A (en) * 2018-05-29 2019-06-11 江苏艾尔康生物医药科技有限公司 A kind of construction method of immunodeficient rats animal model and application
US10463029B1 (en) 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome
JP7504030B2 (en) 2018-06-13 2024-06-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Rodent model of fibrodysplasia ossificans progressiva
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of engineered dh-dh rearrangement and uses thereof
US20210285009A1 (en) 2018-07-13 2021-09-16 The Regents Of The University Of California Retrotransposon-based delivery vehicle and methods of use thereof
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
KR20210049859A (en) * 2018-08-28 2021-05-06 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Methods and compositions for regulating the genome
JP7222075B2 (en) 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Complement factor H gene knockout rats as a model of C3 glomerulopathy
US11407995B1 (en) 2018-10-26 2022-08-09 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US11434477B1 (en) 2018-11-02 2022-09-06 Inari Agriculture Technology, Inc. RNA-guided nucleases and DNA binding proteins
CN109504708A (en) * 2018-12-03 2019-03-22 江苏集萃药康生物科技有限公司 A kind of gene targeting carrier and method of self deletion of selection markers
KR20210105914A (en) 2018-12-20 2021-08-27 리제너론 파마슈티칼스 인코포레이티드 Nuclease-mediated repeat expansion
MX2021008291A (en) 2019-01-17 2021-08-05 Regeneron Pharma A rodent model of mood disorders.
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
US20220145330A1 (en) 2019-02-10 2022-05-12 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Modified mitochondrion and methods of use thereof
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
CA3131145A1 (en) * 2019-02-21 2020-08-27 Nemametrix Inc Monogenic or polygenic disease model organisms humanized with two or more genes
CN113473850A (en) 2019-02-22 2021-10-01 瑞泽恩制药公司 Rodents having genetically modified sodium channels and methods of use thereof
DE212020000516U1 (en) 2019-03-07 2022-01-17 The Regents of the University of California CRISPR-CAS effector polypeptides
SG11202109407XA (en) 2019-03-15 2021-09-29 Regeneron Pharma A loss of function rodent model of solute carrier 39 member 5
JP7669281B2 (en) 2019-03-19 2025-04-28 ザ ブロード インスティテュート，インコーポレーテッド Editing Methods and compositions for editing nucleotide sequences
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
KR20220016869A (en) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 Non-Human Animals Comprising a Humanized TTR Locus with Beta-Slip Mutations and Methods of Use
MX2021014893A (en) 2019-06-05 2022-03-11 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof.
BR112021022722A2 (en) 2019-06-07 2022-01-04 Regeneron Pharma Non-human animal, non-human animal cell, non-human animal genome, humanized non-human animal albumin gene, targeting vector, method of evaluating the activity of a reagent, and, method of optimizing the activity of a reagent
CN114008193A (en) 2019-06-27 2022-02-01 瑞泽恩制药公司 Modeling of TDP-43 proteinopathy
CA3153141A1 (en) * 2019-10-03 2021-04-08 Regeneron Pharmaceuticals, Inc. A crnn loss of function rodent model
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2021129766A1 (en) * 2019-12-25 2021-07-01 江苏集萃药康生物科技股份有限公司 Il-15 humanized mouse model and use thereof
WO2021151073A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
CN115175559A (en) 2020-01-28 2022-10-11 瑞泽恩制药公司 Non-human animals comprising a humanized PNPLA3 locus and methods of use thereof
WO2021158883A1 (en) 2020-02-07 2021-08-12 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
JP2023516052A (en) * 2020-03-04 2023-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Rodent model of B4GALT1-mediated function
CN113355323B (en) * 2020-03-06 2023-07-11 生物岛实验室 Preparation method and application of humanized ACE2 gene modified mouse model
CN113355325B (en) * 2020-03-06 2023-07-14 中国科学院广州生物医药与健康研究院 Preparation method and application of humanized ACE2 gene modified mouse embryonic stem cell model
EP4125348A1 (en) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
CN116075221A (en) 2020-04-21 2023-05-05 瑞泽恩制药公司 Non-human animal with humanized CXCL13 gene
JP2023525304A (en) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
IL301493B2 (en) 2020-10-01 2025-02-01 Regeneron Pharma Rodent animals expressing human cr1
EP4262374A1 (en) 2020-12-21 2023-10-25 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
CN112852875B (en) * 2021-02-26 2022-10-21 福建省立医院 Construction method of CD3e transgenic mouse model for tracing tumor T lymphocyte infiltration
CN113229213B (en) * 2021-05-14 2022-06-14 福州大学 A method for pulmonary embolism modeling and non-invasive quantitative detection by labeling thrombus with near-infrared fluorescent probes
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
CN118632622A (en) 2021-12-08 2024-09-10 瑞泽恩制药公司 Mutant myocilin disease model and its use
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
EP4476245A1 (en) 2022-02-11 2024-12-18 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
EP4514125A1 (en) 2022-04-26 2025-03-05 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
CN120344660A (en) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 Gene editing compositions, systems and methods of use
AU2023310163A1 (en) 2022-07-19 2025-01-16 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
CN116326540A (en) * 2022-12-22 2023-06-27 新疆农业大学 Supplementary feeding method for regulating intestinal health and promoting growth of colts in lactation period
WO2024259354A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025122669A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (en) 1987-04-02 1992-07-31 Amrad Corp Ltd METHOD OF PURIFICATION OF THE LEUKEMIA INHIBITOR FACTOR (LIF) AND PHARMACEUTICAL COMPOSITIONS CONTAINING POLIPEPTIDES WITH LIF ACTIVITY
WO1995006716A1 (en) 1993-08-30 1995-03-09 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
EP0880584A1 (en) 1996-02-16 1998-12-02 University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
CA2354542A1 (en) * 1998-12-31 2000-07-06 The J. David Gladstone Institutes Transgenic rodents and rodent cell lines expressing hiv co-receptors
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
AU2982900A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2004537260A (en) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド Regulation of angiogenesis by zinc finger proteins
JP2005505236A (en) 2000-12-19 2005-02-24 アルトー バイオサイエンス コーポレイション Transgenic animals including humanized immune system
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2002225187A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
ES2432118T3 (en) 2001-02-14 2013-11-29 Abt Holding Company Multipotent adult stem cells, sources of these, methods to obtain and maintain them, methods of differentiation of these, methods of use of these and cells derived from these
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
BRPI0307383B1 (en) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation directed genetic recombination method in host plant cell
CA2479153C (en) 2002-03-15 2015-06-02 Cellectis Hybrid and single chain meganucleases and use thereof
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
JP2006502748A (en) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー Methods of using chimeric nucleases to induce gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
AU2004204509A1 (en) 2003-01-13 2004-07-29 Mario R. Capecchi Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005085427A1 (en) 2004-03-04 2005-09-15 Dainippon Sumitomo Pharma Co., Ltd. Rat embryonic stem cell
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
ATE510006T1 (en) 2004-09-03 2011-06-15 Moraga Biotechnology Inc BLASTOMER-LIKE NON-EMBRYONAL TOTIPOTENT STEM CELLS AND METHODS OF COLLECTION AND USE
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
ES2667169T3 (en) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Method to generate a homozygous non-human animal for genetic modification
FR2879622B1 (en) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech IN VITRO PROCESS FOR THE PRODUCTION OF OOCYTES OR EGGS WITH TARGETED GENOMIC MODIFICATION
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
ATE466933T1 (en) 2005-03-15 2010-05-15 Cellectis I-CREI MEGANUCLEASE VARIANTS WITH MODIFIED SPECIFICITY AND METHOD FOR THEIR PRODUCTION AND USE
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
JP5680850B2 (en) 2006-03-30 2015-03-04 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｕｒｔ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｅｄｉｎｂｕｒｇｈ Culture medium containing kinase inhibitor and use thereof
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101117633B (en) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 Nucleus transplantation method
US9187758B2 (en) 2006-12-14 2015-11-17 Sangamo Biosciences, Inc. Optimized non-canonical zinc finger proteins
US7771967B2 (en) * 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
ATE489465T1 (en) 2007-04-26 2010-12-15 Sangamo Biosciences Inc TARGETED INTEGRATION INTO THE PPP1R12C POSITION
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
JP5908725B2 (en) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for targeted single-strand cleavage and targeted integration
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
US20110030072A1 (en) 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
JP5681114B2 (en) * 2008-12-04 2015-03-04 サンガモ バイオサイエンシーズ， インコーポレイテッド Rat genome editing using zinc finger nuclease
EP3312269A1 (en) 2008-12-17 2018-04-25 The Scripps Research Institute Generation and maintenance of stem cells
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8722964B2 (en) 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US9314005B2 (en) 2009-07-01 2016-04-19 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (SCID)
CN102858985A (en) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 Method for genome editing
KR20120097483A (en) 2009-07-24 2012-09-04 시그마-알드리치 컴퍼니., 엘엘씨 Method for genome editing
WO2011011678A2 (en) 2009-07-24 2011-01-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
WO2011051390A1 (en) 2009-10-28 2011-05-05 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Homologous recombination in the oocyte
PL2494047T3 (en) 2009-10-29 2017-05-31 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
US20120315670A1 (en) 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
EP2508595B1 (en) 2009-12-01 2016-11-23 National Cancer Center Method for constructing chimeric rat using rat embryonic stem cells
EP3456826B1 (en) 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
CN102791865B (en) 2009-12-21 2015-07-01 凯津公司 Improved techniques for transfecting protoplasts
CN102843904B (en) 2010-01-22 2015-01-21 陶氏益农公司 Excision of transgenes in genetically modified organisms
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
EP2579711B1 (en) 2010-06-11 2019-04-17 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012018726A1 (en) 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
US9402377B2 (en) 2010-09-20 2016-08-02 Yale University Human SIRPAalpha transgenic animals and their methods of use
EP2675271B1 (en) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
WO2012129198A1 (en) * 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
US20140304847A1 (en) 2011-06-07 2014-10-09 Ralf Kühn Recombination efficiency by inhibition of nhej dna repair
JP6484444B2 (en) * 2011-08-26 2019-03-13 イエキュリス コーポレーションＹｅｃｕｒｉｓ Ｃｏｒｐｏｒａｔｉｏｎ Fumaryl acetoacetate hydrolase (FAH) deficient and immunodeficient rats and their use
IL315445A (en) 2011-10-28 2024-11-01 Regeneron Pharma Mice with a genetic change in the T cell receptor
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
EP2847335B1 (en) * 2012-04-25 2018-06-27 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
DE102012103797A1 (en) 2012-04-30 2013-10-31 KRAH Elektronische Bauelemente GmbH Liquid cooled resistor
KR102116153B1 (en) 2012-05-07 2020-05-27 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for nuclease-mediated targeted integration of transgenes
LT2800811T (en) 2012-05-25 2017-09-11 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2013188522A2 (en) 2012-06-12 2013-12-19 Genentech, Inc. Methods and compositions for generating conditional knock-out alleles
CN116622704A (en) 2012-07-25 2023-08-22 布罗德研究所有限公司 Inducible DNA-binding proteins and genome interference tools and their applications
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2014093479A1 (en) 2012-12-11 2014-06-19 Montana State University Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
CN119752887A (en) 2012-12-12 2025-04-04 布罗德研究所有限公司 Systems, methods and engineering of optimized guidance compositions for sequence manipulation
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP3705490B1 (en) 2012-12-12 2024-03-06 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
CN110982844B (en) 2012-12-12 2024-08-13 布罗德研究所有限公司 CRISPR-CAS component systems, methods, and compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
ES2576126T3 (en) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modification by genetic technology and optimization of improved enzyme systems, methods and compositions for sequence manipulation
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
SG10201704932UA (en) 2012-12-17 2017-07-28 Harvard College Rna-guided human genome engineering
ES2953523T3 (en) 2012-12-27 2023-11-14 Keygene Nv Method for inducing a directed translocation in a plant
WO2014127287A1 (en) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Method for in vivo tergated mutagenesis
CA2900992C (en) 2013-02-20 2023-02-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
ES2749624T3 (en) 2013-03-14 2020-03-23 Caribou Biosciences Inc Nucleic Acid Targeted Nucleic Acid Compositions and Methods
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
JP6346266B2 (en) 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2016522679A (en) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing with the CRISPR / Cas system
PL3456831T3 (en) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
EP2986709A4 (en) 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
EP2796558A1 (en) 2013-04-23 2014-10-29 Rheinische Friedrich-Wilhelms-Universität Bonn Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants
JP2016518142A (en) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド Delivery methods and compositions for nuclease-mediated genomic gene manipulation
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
DK3004349T3 (en) 2013-05-29 2018-06-06 Cellectis Sa A method for producing precise DNA cleavage using CAS9 nickase activity
DK3309248T3 (en) 2013-05-29 2021-08-02 Cellectis Method for manipulating T cells for immunotherapy using an RNA-guided CAS nuclease system
ES2883131T3 (en) 2013-05-29 2021-12-07 Cellectis Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
US20140359795A1 (en) 2013-05-31 2014-12-04 Recombinetics, Inc. Genetic techniques for making animals with sortable sperm
WO2014201015A2 (en) 2013-06-11 2014-12-18 The Regents Of The University Of California Methods and compositions for target dna modification
KR20160044457A (en) 2013-06-17 2016-04-25 더 브로드 인스티튜트, 인코퍼레이티드 Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP3011035B1 (en) 2013-06-17 2020-05-13 The Broad Institute, Inc. Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
KR20160030187A (en) 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
BR122021009076B1 (en) 2013-06-17 2024-02-15 The Broad Institute Inc. VIRAL VECTOR CONTAINING HETEROLOGOUS NUCLEIC ACID MOLECULE(S), COMPOSITION, USE AND METHODS THEREOF
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
DK3011032T3 (en) 2013-06-17 2020-01-20 Broad Inst Inc MANUFACTURING, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETING AGAINST AND MODELING DISEASES AND DISORDERS IN POSTMITOTIC CELLS
US20160145645A1 (en) 2013-06-19 2016-05-26 Sigma-Aldrich Co. Llc Targeted integration
JP2016528890A (en) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing using the CRISPR / Cas system
JP7120717B2 (en) 2013-07-09 2022-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ Multiple RNA-guided genome editing
CA3218040A1 (en) 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US9663782B2 (en) 2013-07-19 2017-05-30 Larix Bioscience Llc Methods and compositions for producing double allele knock outs
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
WO2015026887A1 (en) 2013-08-22 2015-02-26 E. I. Du Pont De Nemours And Company A soybean u6 polymerase iii promoter and methods of use
KR20160060659A (en) 2013-08-29 2016-05-30 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Methods and compositions for rna-guided treatment of hiv infection
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150079680A1 (en) 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
JP5900942B2 (en) 2013-11-06 2016-04-06 国立大学法人広島大学 Nucleic acid insertion vector
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
AU2014356400A1 (en) 2013-11-28 2016-06-02 Horizon Discovery Limited Somatic haploid human cell line
MX388127B (en) 2013-12-11 2025-03-19 Regeneron Pharma METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME.
JP2017503485A (en) 2013-12-12 2017-02-02 ザ・ブロード・インスティテュート・インコーポレイテッド CRISPR-CAS system and method for altering gene product expression, structural information, and inducible modular CAS enzyme
EP3079726B1 (en) 2013-12-12 2018-12-05 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
RU2016128077A (en) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. DELIVERY, APPLICATION AND APPLICATIONS IN THE THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TREATMENT OF CONDITIONED HBV AND VIRAL DISEASES AND DISORDERS
WO2015089354A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
ES2765481T3 (en) 2013-12-12 2020-06-09 Broad Inst Inc Administration, use and therapeutic applications of crisp systems and compositions for genomic editing
JP6542226B2 (en) 2013-12-13 2019-07-10 セレクティス A new method to select algal transformed cells using nucleases
EP3083958B1 (en) 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
CN106133141B (en) 2014-01-08 2021-08-20 哈佛学院董事及会员团体 RNA-guided gene drives
CA2936976A1 (en) 2014-01-24 2015-07-30 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
US20150291969A1 (en) 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
US10233456B2 (en) 2014-01-30 2019-03-19 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
HRP20201040T1 (en) 2014-02-11 2021-01-08 The Regents Of The University Of Colorado, A Body Corporate Crispr enabled multiplexed genome engineering
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US20170106055A1 (en) 2014-03-12 2017-04-20 Precision Biosciences, Inc. Dystrophin Gene Exon Deletion Using Engineered Nucleases
PT3116305T (en) 2014-03-14 2024-03-07 Cibus Us Llc Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US10349639B2 (en) 2014-03-26 2019-07-16 University Of Maryland, College Park Targeted genome editing in zygotes of domestic large animals
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
KR101823661B1 (en) 2014-04-24 2018-01-30 기초과학연구원 A method of selecting a nuclease target sequence for gene knockout based on microhomology
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015173436A1 (en) 2014-05-16 2015-11-19 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
JP2017518075A (en) 2014-05-30 2017-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Compositions and methods for treating latent viral infections
WO2015188109A1 (en) 2014-06-06 2015-12-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
SG11201610405RA (en) 2014-06-16 2017-01-27 Univ Johns Hopkins Compositions and methods for the expression of crispr guide rnas using the h1 promoter
US9902971B2 (en) 2014-06-26 2018-02-27 Regeneron Pharmaceuticals, Inc. Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016011428A1 (en) 2014-07-17 2016-01-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating cells containing fusion genes
US9944933B2 (en) 2014-07-17 2018-04-17 Georgia Tech Research Corporation Aptamer-guided gene targeting
DK3186376T3 (en) 2014-08-27 2019-05-06 Caribou Biosciences Inc METHODS FOR IMPROVING CAS9-MEDIATED MANIPULATION EFFICIENCY
US20180216098A1 (en) 2014-08-27 2018-08-02 New England Biolabs, Inc. Synthon Formation
EP3188763B1 (en) 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification
BR112017001601A2 (en) 2014-09-07 2017-11-21 Selecta Biosciences Inc methods and compositions for attenuating immune responses of the modulating antiviral transfer vector of gene expression
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
CN107002098A (en) 2014-09-29 2017-08-01 杰克逊实验室 Genetic modification mammal is produced by electroporation high efficiency, high flux
EP3201340B1 (en) 2014-10-01 2020-12-02 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016061073A1 (en) 2014-10-14 2016-04-21 Memorial Sloan-Kettering Cancer Center Composition and method for in vivo engineering of chromosomal rearrangements
EP3561052A1 (en) 2014-10-15 2019-10-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
EP3207131B1 (en) 2014-10-17 2022-09-28 Howard Hughes Medical Institute Genomic probes
BR112017007923B1 (en) 2014-10-17 2023-12-12 The Penn State Research Foundation METHOD FOR PRODUCING GENETIC MANIPULATION MEDIATED BY MULTIPLEX REACTIONS WITH RNA IN A RECEIVING CELL, CONSTRUCTION OF NUCLEIC ACID, EXPRESSION CASSETTE, VECTOR, RECEIVING CELL AND GENETICALLY MODIFIED CELL
US20170306306A1 (en) 2014-10-24 2017-10-26 Life Technologies Corporation Compositions and Methods for Enhancing Homologous Recombination
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3521437B1 (en) 2014-11-21 2025-01-15 Regeneron Pharmaceuticals, Inc. Methods for targeted genetic modification using paired guide rnas
EP3224363B1 (en) 2014-11-27 2021-11-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid constructs for genome editing
WO2016089866A1 (en) 2014-12-01 2016-06-09 President And Fellows Of Harvard College Rna-guided systems for in vivo gene editing
EP3230452B1 (en) 2014-12-12 2025-06-11 The Broad Institute, Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
MX388784B (en) 2014-12-19 2025-03-20 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION THROUGH SINGLE-STEP MULTIPLE TARGETING.
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
US20180155708A1 (en) 2015-01-08 2018-06-07 President And Fellows Of Harvard College Split Cas9 Proteins
US10280451B2 (en) 2015-01-09 2019-05-07 Bio-Rad Laboratories, Inc. Detection of genome editing
WO2016114972A1 (en) 2015-01-12 2016-07-21 The Regents Of The University Of California Heterodimeric cas9 and methods of use thereof
CN107429263A (en) 2015-01-15 2017-12-01 斯坦福大学托管董事会 The method of controlling gene group editor
SG11201705788TA (en) 2015-01-28 2017-08-30 Pioneer Hi Bred Int Crispr hybrid dna/rna polynucleotides and methods of use
WO2016130697A1 (en) 2015-02-11 2016-08-18 Memorial Sloan Kettering Cancer Center Methods and kits for generating vectors that co-express multiple target molecules
AU2016225179C1 (en) 2015-02-23 2022-11-03 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
JP6871169B2 (en) 2015-03-02 2021-05-12 シナイ ヘルス システム Homologous recombination factor
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
WO2016154579A2 (en) 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Also Published As

Publication number Publication date
PL3456831T3 (en) 2021-12-06
CN105308184B (en) 2020-06-02
KR102186281B1 (en) 2020-12-03
US20190323032A1 (en) 2019-10-24
HRP20211385T1 (en) 2021-12-10
AU2014253942B2 (en) 2020-07-02
AU2014253942B9 (en) 2020-08-13
CY1124627T1 (en) 2022-07-22
SI2986729T1 (en) 2019-02-28
LT2986729T (en) 2018-10-25
CA2908697A1 (en) 2014-10-23
RU2676708C2 (en) 2019-01-10
HUE040575T2 (en) 2019-03-28
EP3456831A1 (en) 2019-03-20
HK1214625A1 (en) 2016-07-29
CN111500630A (en) 2020-08-07
CY1120845T1 (en) 2019-12-11
WO2014172489A3 (en) 2014-12-11
RU2015148637A (en) 2017-05-22
RS62263B1 (en) 2021-09-30
EP2986729B1 (en) 2018-09-19
EP2986729A2 (en) 2016-02-24
US12037596B2 (en) 2024-07-16
JP6411463B2 (en) 2018-10-24
SG11201508028QA (en) 2015-10-29
DK3456831T3 (en) 2021-09-06
IL241856B (en) 2020-09-30
KR20200136508A (en) 2020-12-07
BR112015026197B1 (en) 2022-12-06
PT3456831T (en) 2021-09-10
MY177850A (en) 2020-09-23
DK2986729T3 (en) 2018-10-29
CN105308184A (en) 2016-02-03
US20140309487A1 (en) 2014-10-16
HUE056903T2 (en) 2022-04-28
US10385359B2 (en) 2019-08-20
PL2986729T3 (en) 2019-04-30
WO2014172489A2 (en) 2014-10-23
JP2016515401A (en) 2016-05-30
EP2986729A4 (en) 2016-10-19
US20170204430A1 (en) 2017-07-20
SI3456831T1 (en) 2021-11-30
LT3456831T (en) 2021-09-10
EP3456831B1 (en) 2021-07-14
US20140310828A1 (en) 2014-10-16
HRP20211385T8 (en) 2022-03-04
IL276772A (en) 2020-10-29
SMT202100516T1 (en) 2021-11-12
HRP20181648T1 (en) 2019-01-25
NZ713343A (en) 2021-08-27
MX369747B (en) 2019-11-20
MX2015014487A (en) 2016-07-28
CA2908697C (en) 2023-12-12
ES2699578T3 (en) 2019-02-11
RS58255B1 (en) 2019-03-29
PT2986729T (en) 2018-11-30
SMT201800671T1 (en) 2019-01-11
KR20150141987A (en) 2015-12-21
BR112015026197A2 (en) 2017-10-10
US20210301301A1 (en) 2021-09-30
US10975390B2 (en) 2021-04-13
AU2020233694A1 (en) 2020-10-08
AU2014253942A1 (en) 2015-11-12
ES2888250T3 (en) 2022-01-03

Similar Documents

Publication Publication Date Title
SG10201808935WA (en) Targeted modification of rat genome
MX2021014368A (en) Methods and compositions for the targeted modification of a genome.
MX353134B (en) Genetically modified t cell receptor mice.
EP4249074A3 (en) Genomic engineering of pluripotent cells
CY1121657T1 (en) METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND FOR RNA-DIRECTED REGULATION OF TRANSCRIPTION
SA519410244B1 (en) Tissue selective transgene expression
EP4321623A3 (en) Methods and compositions for genome editing in non-dividing cells
MX362523B (en) Nuclease-mediated targeting with large targeting vectors.
WO2016201047A8 (en) Crispr/cas-related methods and compositions for improving transplantation
EP2534163A4 (en) TARGETED GENOMIC MODIFICATION WITH PARTIALLY MONOCATERIC DONOR MOLECULES
SG10201811116UA (en) Non-human animals having a humanized programmed cell death 1 gene
BR112017013104A2 (en) methods for modifying a target genomic locus in a cell, for enhancing homologous recombination at a target genomic locus in a cell, and for producing an f0 generation from a nonhuman animal.
IN2015DN01785A (en)
MX347575B (en) Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering.
CY1121367T1 (en) METHODS AND COMPOSITIONS FOR TARGETED GENOMIC MODIFICATION
NZ719493A (en) Compositions and methods for producing genetically modified animals
NZ730667A (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
NZ750842A (en) Plant regulatory elements and uses thereof